Sanofi Plavix Patent: Generic Firms Raise "Substantial Challenge" To Validity, Aventis Says

Analyses of the clopidogrel patent litigation suggest Dr. Reddy's and Apotex raise "serious questions" on anticipation, obviousness and "double patenting," Aventis says. Reviews are part of Aventis' ongoing defense against Sanofi's hostile takeover bid.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet